Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
Current Value
$8.901 Year Return
Current Value
$8.901 Year Return
Market Cap
$1.40B
P/E Ratio
-6.76
1Y Stock Return
307.31%
1Y Revenue Growth
6.45%
Dividend Yield
0.00%
Price to Book
4.0
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
LNG | -15.91% | $49.37B | +24.99% | 0.82% |
GAN | -13.82% | $83.39M | +21.19% | 0.00% |
WHLM | -13.46% | $17.64M | -29.34% | 0.00% |
BACK | -11.53% | $1.76M | -32.90% | 0.00% |
CBOE | -9.63% | $21.46B | +15.84% | 1.11% |
CI | -9.16% | $89.70B | +12.57% | 1.68% |
ALL | -9.14% | $52.06B | +45.67% | 1.85% |
NOC | -8.73% | $71.54B | +4.23% | 1.60% |
KDP | -8.67% | $42.76B | -1.22% | 2.77% |
COR | -8.65% | $47.48B | +21.20% | 0.86% |
ARLP | -8.64% | $3.54B | +26.77% | 10.11% |
RNR | -8.60% | $13.74B | +23.09% | 0.58% |
HUSA | -8.02% | $16.69M | -11.56% | 0.00% |
ACGL | -7.36% | $36.00B | +16.84% | 0.00% |
NEUE | -7.26% | $40.93M | -34.13% | 0.00% |
PGR | -6.97% | $149.10B | +57.29% | 0.45% |
XPEL | -6.91% | $1.18B | -7.73% | 0.00% |
UNM | -6.79% | $13.16B | +69.20% | 2.16% |
LMT | -6.57% | $126.40B | +18.99% | 2.36% |
PG | -6.53% | $402.15B | +14.14% | 2.33% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PAYC | 0.03% | $12.12B | +21.78% | 0.69% |
STKL | 0.07% | $894.47M | +55.49% | 0.00% |
ASPS | -0.12% | $22.36M | -80.26% | 0.00% |
MOH | 0.21% | $16.16B | -21.56% | 0.00% |
CME | 0.21% | $82.76B | +9.21% | 1.98% |
CB | 0.23% | $114.43B | +26.00% | 1.24% |
LUMO | 0.23% | $37.45M | +41.97% | 0.00% |
MNOV | 0.24% | $93.19M | +2.15% | 0.00% |
ARC | 0.26% | $146.66M | +18.95% | 5.90% |
SNY | -0.26% | $120.34B | +3.11% | 4.25% |
DXYZ | 0.28% | - | - | 0.00% |
EDSA | -0.31% | $7.11M | -21.79% | 0.00% |
VRSK | -0.33% | $39.77B | +17.45% | 0.53% |
VIRT | -0.40% | $3.17B | +110.38% | 2.60% |
RSG | -0.43% | $66.05B | +31.79% | 1.04% |
KHC | 0.50% | $36.98B | -10.45% | 5.23% |
TTE | -0.50% | $138.45B | -11.95% | 5.50% |
KMB | 0.54% | $45.22B | +11.57% | 3.58% |
PSQH | 0.54% | $79.26M | -57.46% | 0.00% |
ELV | 0.60% | $91.42B | -16.23% | 1.61% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
RCUS | 45.31% | $1.33B | +5.07% | 0.00% |
EYPT | 45.25% | $492.90M | +50.49% | 0.00% |
TEM | 44.51% | $8.50B | 0.00% | 0.00% |
PLRX | 42.04% | $778.32M | -9.55% | 0.00% |
ORC | 41.22% | $615.55M | +6.95% | 18.46% |
ARWR | 38.59% | $2.31B | -34.44% | 0.00% |
ALDX | 35.89% | $294.18M | +102.46% | 0.00% |
OMER | 35.67% | $349.44M | +258.93% | 0.00% |
KROS | 35.57% | $2.17B | +73.87% | 0.00% |
BAK | 35.20% | $878.18M | -36.93% | 0.00% |
DX | 34.68% | $991.29M | +9.75% | 12.54% |
CRNX | 34.45% | $5.12B | +84.27% | 0.00% |
SAIC | 34.41% | $5.92B | +3.71% | 1.24% |
VIR | 34.37% | $954.40M | -26.51% | 0.00% |
RCKT | 34.11% | $1.20B | -39.83% | 0.00% |
ARQT | 34.05% | $1.18B | +433.86% | 0.00% |
YMAB | 34.02% | $486.41M | +106.46% | 0.00% |
ALEC | 33.93% | $377.04M | -19.46% | 0.00% |
MMI | 33.87% | $1.58B | +23.86% | 1.24% |
NXDT | 33.77% | $218.01M | -37.42% | 11.58% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
PTH | 51.42% | $143.31M | 0.6% |
XBI | 50.31% | $6.58B | 0.35% |
XPH | 49.81% | $157.87M | 0.35% |
PBE | 46.72% | $258.53M | 0.58% |
GNOM | 46.63% | $70.59M | 0.5% |
IBB | 46.18% | $6.66B | 0.45% |
IWO | 44.28% | $12.56B | 0.24% |
FBT | 43.37% | $1.11B | 0.56% |
IWC | 42.20% | $933.99M | 0.6% |
VBK | 41.62% | $19.31B | 0.07% |
VTWO | 41.43% | $12.38B | 0.1% |
BBH | 41.26% | $397.87M | 0.35% |
IWM | 41.00% | $75.73B | 0.19% |
ISCG | 40.64% | $640.00M | 0.06% |
VXF | 40.30% | $21.54B | 0.06% |
NUSC | 40.25% | $1.27B | 0.31% |
KOMP | 40.19% | $2.09B | 0.2% |
ARKG | 39.46% | $1.13B | 0.75% |
ESML | 39.44% | $1.90B | 0.17% |
SMLF | 39.38% | $1.44B | 0.15% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -30.33% | $388.04M | 1.43% |
VIXY | -19.23% | $195.31M | 0.85% |
DBA | -16.02% | $755.88M | 0.93% |
USDU | -12.77% | $201.97M | 0.5% |
SOYB | -12.76% | $27.32M | 0.22% |
CORN | -11.63% | $61.12M | 0.2% |
USCI | -10.06% | $185.47M | 1.07% |
KRBN | -9.93% | $242.47M | 0.85% |
EQLS | -9.38% | $76.08M | 1% |
KMLM | -9.09% | $353.87M | 0.9% |
UUP | -8.62% | $309.25M | 0.77% |
TAIL | -8.04% | $67.98M | 0.59% |
WEAT | -7.84% | $120.27M | 0.28% |
MINT | -7.55% | $11.62B | 0.35% |
CTA | -7.33% | $350.27M | 0.78% |
CSHI | -6.07% | $482.85M | 0.38% |
SEIX | -5.62% | $268.81M | 0.62% |
AGZD | -5.38% | $142.76M | 0.23% |
HDRO | -4.42% | $164.26M | 0.3% |
IBDP | -3.88% | $2.11B | 0.1% |
Yahoo
Ocular Therapeutix Inc (OCUL) reports robust cash reserves and significant trial advancements, despite regulatory and pricing challenges.
Yahoo
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -13.04% and 12.76%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Yahoo
BEDFORD, Mass. AP) — Ocular Therapeutix Inc. OCUL) on Thursday reported a loss of $36.5 million in its third quarter.
Yahoo
SOL-1 expected to be fully randomized by YE 2024 with topline data expected in Q4 2025 Active clinical trial sites now enrolling patients directly into SOL-R Cash balance of $427.2M as of September 30, 2024, expected to fund operations into 2028 Ocular to host a Q3 2024 conference call and webcast today, November 14th, at 8:00 AM ET BEDFORD, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improvin
SeekingAlpha
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ETCompany ParticipantsBill Slattery - VP, IRPravin Dugel -...
Yahoo
Harrow (HROW) delivered earnings and revenue surprises of -140% and 11.42%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
FMF | 0.05% | $244.61M | 0.95% |
DBB | 0.16% | $126.37M | 0.77% |
FTGC | 0.20% | $2.17B | 1.02% |
SGOV | -0.28% | $27.53B | 0.09% |
XHLF | -0.35% | $874.27M | 0.03% |
CANE | 0.57% | $17.72M | 0.29% |
XBIL | -0.73% | $637.70M | 0.15% |
TBIL | -0.89% | $4.38B | 0.15% |
JUCY | 1.00% | $324.29M | 0.6% |
BCI | 1.08% | $1.20B | 0.26% |
PDBC | 1.17% | $4.40B | 0.59% |
TPMN | 1.30% | $40.60M | 0.65% |
KCCA | 1.42% | $220.51M | 0.87% |
GSG | 1.46% | $914.42M | 0.75% |
BCD | 1.55% | $245.02M | 0.3% |
DBC | 1.93% | $1.39B | 0.87% |
DBO | 2.18% | $217.57M | 0.77% |
HIGH | -2.43% | $302.78M | 0.51% |
KLIP | 2.47% | $125.85M | 0.93% |
BILZ | 2.48% | $563.02M | 0.14% |